U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid

OMB control number.

	Substitute for forr	m 144	19/PTO	Complete if Known		
	INFORMATION D	ISCI	OSURE	Application Number	10/560953	
	STATEMENT BY			Filing Date	6/16/2004	
_			47 2040	First Named Inventor	Beverly L. Wolgast	
D:	Date Submitted: November 17, 2010			Art Unit	1624	
(1	use as many sheet	s as	necessary)	Examiner Name	COLEMAN, BRENDA LIBBY	
Sheet	1	of	2	Attorney Docket Number	098817-0642	

	U.S. PATENT DOCUMENTS									
Examin	Cite	Document Number	Publication Date	Name of Patentee or Applicant of	Pages, Columns, Lines, of Where Relevant					
er Initials*	No.1	Number-Kind Code ² (if	MM-DD-YYYY	Cited Document	Passages or Relevant					
3111(1215		known) তেন্ত্রত্তিহ্নিত্তিক ্তি	02.28.1072	Hoogada Karl duplica	Figures Appear te					
t		60/470,280	N/Δ	Smith et al	The second secon					
no da	:e ///	**************************************	N/A	Burbaum et al						
ıte	A40	00/012,001	NVA	Arena Pharmaceutical	200000000000000000000000000000000000000					
o date	≥ /\\1	61/268 930	N/A	Arena Pharmaceutical						
	00000000000000000000000000000000000000	onething the properties of the		Charbaqui et al						
*************	, 140	2040/0473804	07.08.2010	Smith et al duplica	lte					
***************************************	7100		aya yiyandama ee garaa qaraa sagaa ee sagaa qaadda yaab ma <mark>aannan aadada siibahah issa da</mark> a anaalaa ^{ah} aga ar aanabaasa saa							
appear and the state of the sta		as a sus juminint riangini daringa kanada jumini 17 denna amara mara mara mahalajambahahahahahahahahahahahahahahahahahaha								
pathways (et a patricular and an extract broad	and the second s									

	UNPUBLISHED U.S. PATENT APPLICATION DOCUMENTS							
Examiner Initials*	Cite No.1	U.S. Patent Application Document Serial Number-Kind Code ² (If known)	Filing Date of Cited Document MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear			
	ranna and dawn a para 1907 / A	(ii Ariowi)						

T	FOREIGN PATENT DOCUMENTS									
	Examiner Cite Initials' No.1 duplicate		Foreign Patent Document Country Code ³⁻ Number ⁴⁻ Kind Code ⁵ (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Documents	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear				
	***************************************			12-15-1970	CIBA GEIGY AG [CH]	***************************************				
* *	/B.C./	B74	JP 62-267250	11-19-1987	PFIZER LTD.					
* *	/B C /	B75	JP 2000-44533	02-15-2000	Mita Shirou, et al.					
e 94	/RC/	B76	JP 2-502723	08-30-1990	SCHERING PLOUGH CORP					
* *	/B.C./	B77	JP 2001-89472	04-03-2001	HOFFMANN LA ROCHE	may make the second of the sec				
1										

NON PATENT LITERATURE DOCUMENTS

Examiner Signature	/Brenda Coleman/	Date Consid	dered 01/25/2011

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. 6 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid

OMB control number.

	Substitute for for	rm 144	19/PTO	Co	Complete if Known		
	INFORMATION I	DISCI	LOSURE	Application Number	10/560953		
	STATEMENT BY	/ APF	LICANT	Filing Date	6/16/2004		
_	N O . L W L M		47 0040	First Named Inventor	Beverly L. Wolgast		
Date Submitted: November 17, 2010			ier 17, 2010	Art Unit	1624		
	(use as many shee	ts as	necessary)	Examiner Name	COLEMAN, BRENDA LIBBY		
Sheet	2	of	2	Attorney Docket Number	098817-0642		

_				
	Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ⁶
	/B.C./	C109	CASY, et al., "Some Arylalkylamino Analogs Of Acyclic Analgetics", J Med Chem., (1968) ,11(3):599-601	
	3	_C110	GHANG, et al., "Becamine Receptor Binding Proporties of Some 2,3,4,5 Tetrahydro 1H-3- Benzazepine-7-ols With Non-Aromatic Substituents In The 5-Position", <i>Bioorganic & Med. Chem.</i>	
	dupli	cate	Letters, (1992) 2(5);399-402	
100000	000000000000000000000000000000000000000	***************************************	LADD, et al., "Synthesis and Departmental Binding of 2-Anyldopamine Analogues: Phenethylamines.	0000000000
	dupli	căt'e	3-Benzazepines, and 9-(Aminomethyl)flourenes", J. Med. Chem., (1986) 29(10):1904-1912	
	000000000000000000000000000000000000000	000000000000000000000000000000000000000	TIETZE, et al., "Efficient Cynthesis of 2,3,4,5 Tetrabydro 11/3 bonzazapinas by Intramolecular Heck	0000000000
	dupli	catle	Reaction", J. of Synthetic Organic Chem., (1993) pp. 876-880, Thieme Stuttgart, New York	
	/B.C./	C113	U.S. Application Serial No. 11/599,050 - Final Office Action dated August 20, 2010	
	/B.C./	C114	U.S. Application Serial No. 11/793,941- Non-final Office Action (Restriction Requirement) dated September 17, 2010	The state of the s
	To annual state of the state of	eranamenta e e e e e e e e e e e e e e e e e e e		
	a la Barra de la referencia de la composición del composición de la composición de la composición de la composición del composición de la			

			T. C.
Exam Signa	 /Brenda Coleman/	Date Considered	01/25/2011

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04, 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. 6 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.